Physician profile
Michael Azrin
NPI 1558367938
$1,395.62
in general payments reported to CMS, 2019-2025
12 companies · $194 in 2025
The $194 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $272 · 2021: $59.17 · 2022: $152 · 2023: $123 · 2024: $438 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $337.66 | 2020-2024 | |
| Shockwave Medical, INC | $331.00 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abbott Laboratories | $252.25 | 2020-2024 | Jot Dx, Xience Skypoint, Amplatzer Piccolo |
| Asahi Intecc USA, INC. | $125.00 | 2019 | |
| Teleflex LLC | $98.04 | 2023 | Guideliner |
| Bard Peripheral Vascular, INC. | $76.41 | 2025 | Fluency Endovascular Stent Graft |
| Abiomed | $58.01 | 2020-2024 | Impella |
| Amgen INC. | $32.50 | 2019 | |
| Cardiovascular Systems INC. | $27.16 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.10 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.89 | 2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $15.60 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Azrin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.